Lux Biosciences completes patient enrollment in their Phase III clinical trial for the prevention of corneal transplant rejection.
- Published in:
- Expert Review of Clinical Immunology, 2009, v. 5, n. 3, p. 231
- Publication type:
- Article
Works matching DE "LUX Biosciences Inc."
Results: 5
1
2
INDUSTRY NEWS IN BRIEF.
- Published in:
- Ocular Surgery News, 2010, v. 28, n. 6, p. 41
- By:
- Publication type:
- Article
3
ISA 247.
- Published in:
- Drugs in R&D, 2007, v. 8, n. 2, p. 103, doi. 10.2165/00126839-200708020-00005
- Publication type:
- Article
4
LX211 could be the first approved oral treatment to control uveitis inflammation.
- Published in:
- Expert Review of Ophthalmology, 2009, v. 4, n. 6, p. 578
- Publication type:
- Article
5
Lux Biosciences develop first oral drug to reduce inflammation and recurrence in uveitis.
- Published in:
- Expert Review of Ophthalmology, 2009, v. 4, n. 3, p. 220
- Publication type:
- Article